Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi Final Efficacy Results of a Randomized Phase II Study of Recombinant Interleukin-21 Compared to Decarbonize in Patients with Recurrent or Metastatic Melanoma
*Corresponding Author:
Copyright: © 2019 . This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Abstract
Interleukin-21(IL-21) is a T-cell derived cytokine with antitumour activity
dependent on NK cells or CD8+ T cells. A previous phase II study demonstrated
an overall response rate (ORR) of 22.5% in previously untreated patients with
metastatic melanoma. We conducted a multi-centre randomized phase II study in
metastatic melanoma patients to evaluate the efficacy, toxicity, immunogenicity
and biomarkers associated with response to IL-21 versus dacarbazine (DTIC).
